DelveInsight Reports on Medical Marijuana and Cannabidiol Pipeline

Market research firm DelveInsight has published a new report providing comprehensive insights into the current state and future prospects of medical marijuana and cannabidiol (CBD) drug development.

The report, titled “Medical Marijuana - Cannabidiol – Pipeline Insight, 2026,” analyzes the pipeline of over 25 companies and more than 50 drugs in development. It covers products in various stages, from preclinical research to clinical trials, examining factors such as product type, development stage, route of administration, and molecule type. The report also identifies inactive pipeline products in the field.

Research into medical marijuana and its components, particularly cannabinoids like CBD, has been expanding due to their therapeutic potential for a range of conditions, including chronic pain, cancer, inflammatory disorders, and epilepsy. While the U.S. Food and Drug Administration (FDA) has not approved the marijuana plant itself as medicine, it has approved cannabinoid-based medications, such as the epilepsy drug Epidiolex.

DelveInsight's report offers a detailed assessment of the market and clinical evaluations within the medical marijuana and cannabidiol sector. It includes profiles of drugs in development, outlining their mechanisms of action, ongoing clinical studies, and other product-related activities. The analysis also highlights recent industry news and collaborations.